Enteropathic Spondylitis: Difference between revisions

No edit summary
No edit summary
Line 18: Line 18:
* 8-14/100,000 and 120-200/100,000 for underdeveloped countries UC.
* 8-14/100,000 and 120-200/100,000 for underdeveloped countries UC.
Rheumatic manifestations are the most frequent extraintestinal manifestation in IBD patients with a prevalence ranging between 17% and 39%  
Rheumatic manifestations are the most frequent extraintestinal manifestation in IBD patients with a prevalence ranging between 17% and 39%  
 
* The joint involvement observed in IBD is usually classified in two subsets: axial (including [[sacroiliitis]] with or without spondylitis) and peripheral.  
The joint involvement observed in IBD is usually classified in two subsets: axial (including sacroiliitis with or without spondylitis) and peripheral.  
* The axial involvement is found to be present in 2%–16% of IBD patients, with a higher prevalence in CD patients than in UC ones.  
 
* The prevalence of sacroiliitis (asymptomatic and symptomatic) is between 12% and 20% and association with HLA-B27 ranged from 3.9% to 18.9%.  
The axial involvement is found to be present in 2%–16% of IBD patients, with a higher prevalence in CD patients than in UC ones.  
* The peripheral involvement is a common complication in both CD and UC and its prevalence has been reported in a wide range (0.4%–34.6%) of patients with IBD. Predominantly affects the joints of the lower limbs.  
 
* Women show more frequently a peripheral joint involvement, whereas men tend to have an axial involvement.
The prevalence of sacroiliitis (asymptomatic and symptomatic) is between 12% and 20% and association with HLA-B27 ranged from 3.9% to 18.9%.  
* Potential risk factors for arthritis in IBD patients are active bowel disease, family history of IBD, appendectomy, [[Smoking Cessation and Brief Intervention|cigarette smoking]], and the presence of others extraintestinal manifestations, such as erythema nodosum or pyoderma gangrenosum<ref name=":1" />
 
The peripheral involvement is a common complication in both CD and UC and its prevalence has been reported in a wide range (0.4%–34.6%) of patients with IBD. Predominantly affects the joints of the lower limbs.  
 
Women show more frequently a peripheral joint involvement, whereas men tend to have an axial involvement.
 
Potential risk factors for arthritis in IBD patients are active bowel disease, family history of IBD, appendectomy, cigarette smoking, and the presence of others extraintestinal manifestations, such as erythema nodosum or pyoderma gangrenosum<ref name=":1" />


== Mechanism of Injury / Pathological Process  ==
== Mechanism of Injury / Pathological Process  ==
* The pathogenesis of EA is not fully understood - observationally joint inflammation occurs in genetically predisposed subjects with bacterial gut infections (providing important evidence for a possible relationship between inflammation of the gut mucosa and arthritis).  
* The pathogenesis of EA is not fully understood - observationally joint inflammation occurs in genetically predisposed subjects with bacterial gut infections (providing important evidence for a possible relationship between inflammation of the gut mucosa and arthritis).  
* More than two-third of patients with SpA (spondyloarthritis) show microscopic inflammatory changes of gut mucosa without clinical signs of gastrointestinal disease.
* More than two-third of patients with SpA ([[spondyloarthritis]]) show microscopic inflammatory changes of gut mucosa without clinical signs of gastrointestinal disease.
* Current theories prepose that genetically predisposed subjects have an aberrant migration of intestinal lymphocytes or macrophages from inflamed gut mucosa to joints.  
* Current theories prepose that genetically predisposed subjects have an aberrant migration of intestinal [[Immune System|lymphocytes or macrophages]] from inflamed gut mucosa to joints.  
* A dysfunctional interaction between the mucosal immune system and gut bacteria could result in an abnormal state of immunological tolerance toward flora by alterations in mucosal effector cells or by affecting regulatory cells.<ref name=":1">Peluso R, Di Minno MN, Iervolino S, Manguso F, Tramontano G, Ambrosino P, Esposito C, Scalera A, Castiglione F, Scarpa R. [https://www.hindawi.com/journals/jir/2013/631408/ Enteropathic spondyloarthritis: from diagnosis to treatment.] Clinical and Developmental Immunology. 2013 Jan 1;2013.Available from:https://www.hindawi.com/journals/jir/2013/631408/ (last accessed 3.7.2020)</ref>  
* A dysfunctional interaction between the mucosal immune system and gut bacteria could result in an abnormal state of immunological tolerance toward flora by alterations in mucosal effector cells or by affecting regulatory cells.<ref name=":1">Peluso R, Di Minno MN, Iervolino S, Manguso F, Tramontano G, Ambrosino P, Esposito C, Scalera A, Castiglione F, Scarpa R. [https://www.hindawi.com/journals/jir/2013/631408/ Enteropathic spondyloarthritis: from diagnosis to treatment.] Clinical and Developmental Immunology. 2013 Jan 1;2013.Available from:https://www.hindawi.com/journals/jir/2013/631408/ (last accessed 3.7.2020)</ref>  


Line 40: Line 34:


The symptoms of enteropathic arthritis (EnA) can be divided in two groups:
The symptoms of enteropathic arthritis (EnA) can be divided in two groups:
# Symptoms of inflammatory bowel disease (IBD) see Link
# Symptoms of [[Irritable Bowel Syndrome|inflammatory bowel disease]] (IBD) see Link
# Arthritic symptoms in the joints and, possibly, see below.<ref name=":0" />  
# Arthritic symptoms in the joints and, possibly, see below.<ref name=":0" />  
* About one in five people with EnA will have inflammatory arthritis in one or more peripheral (limb) joints eg an arm or leg, lower limbs are more commonly affected.  
* About one in five people with EnA will have inflammatory arthritis in one or more peripheral (limb) joints eg an arm or leg, lower limbs are more commonly affected.  
* The severity of the peripheral arthritis normally coincides with the severity of the IBD, thus when diarrhea and abdominal pain are flaring, the peripheral arthritis tends to flare, as well.
* The severity of the peripheral arthritis normally coincides with the severity of the IBD, thus when diarrhea and abdominal pain are flaring, the peripheral arthritis tends to flare, as well.
* About one in six people with IBD also has spinal inflammation,  this is independent of the severity of the bowel disease symptoms.  
* About one in six people with IBD also has spinal inflammation,  this is independent of the severity of the bowel disease symptoms.  
* In many people, this may just be arthritis in the sacroiliac (SI) joints, but in about five percent of people, the entire spine is involved.
* In many people, this may just be arthritis in the [[Sacroiliac Joint|sacroiliac (SI) joints]], but in about five percent of people, the entire spine is involved.
Note that arthritis symptoms may precede the IBD symptoms<ref name=":0" />.
Note that arthritis symptoms may precede the IBD symptoms<ref name=":0" />.


Line 53: Line 47:
* A stool culture may be taken if a diagnosis of an inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease has not yet been established.
* A stool culture may be taken if a diagnosis of an inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease has not yet been established.
* A colonoscopy with or without bowel biopsies.
* A colonoscopy with or without bowel biopsies.
* Blood tests may be done including an erythrocyte sedimentation rate (ESR or SED Rate), which may help in detecting inflammation, a test to determine the presence of the HLA-B27 genetic marker, and/or a C-reactive protein, which is another test that may help detect the presence of inflammation in the body.
* [[Blood Tests|Blood tests]] may be done including an erythrocyte sedimentation rate (ESR or SED Rate), which may help in detecting inflammation, a test to determine the presence of the HLA-B27 genetic marker, and/or a C-reactive protein, which is another test that may help detect the presence of inflammation in the body.
* Synovial fluid may be taken from affected joints for study.
* Synovial fluid may be taken from affected joints for study.
* X-rays of affected joints.<ref name=":1" />
* X-rays of affected joints.<ref name=":1" />
Line 59: Line 53:
== Management / Interventions  ==
== Management / Interventions  ==


A common treatment regimen for the various forms of spondyloarthritis (ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis, reactive arthritis, juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves  
A common treatment regimen for the various forms of spondyloarthritis ([[Ankylosing Spondylitis|ankylosing spondylitis]], [[Psoriatic Arthritis|psoriatic arthritis]], enteropathic arthritis, [[Reactive Arthritis|reactive arthritis]], juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves  


Medication -  
Medication -  
* In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted so the gastrointestinal component of the disease is also treated and not exacerbated.
* In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted so the gastrointestinal component of the disease is also treated and not exacerbated.
* The use of corticosteroids and/or DMARDs and/or of anti-TNFα, helpful to contain intestinal inflammation, usually leads also to the reduction of peripheral arthritis symptoms.
* The use of corticosteroids and/or [[DMARDs in the Management of Rheumatoid Arthritis|DMARDs]] and/or of anti-TNFα, helpful to contain intestinal inflammation, usually leads also to the reduction of peripheral arthritis symptoms.
* Intra-articular injections of steroids<ref name=":1" />
* [[Therapeutic Corticosteroid Injection|Intra-articular injection]]<nowiki/>s of [[Corticosteroid Medication|steroids]]<ref name=":1" />
Physical therapy - including
Physical therapy - including
* Exercise (strength and range of movement)
* [[Therapeutic Exercise|Exercise]] (strength and range of movement)
* Good posture practices
* Good [[posture]] practices
* Mobilisations and massage
* Mobilisations and [[massage]]
* Other options eg heat/cold to help relax muscles and reduce joint pain<ref name=":0" />.  
* Other options eg heat/cold to help relax muscles and reduce joint pain<ref name=":0" />.  


== Differential Diagnosis  ==
== Key Evidence   ==
 
add text here relating to the differential diagnosis of this condition<br>
 
== Key Evidence ==
 
add text here relating to key evidence with regards to any of the above headings<br>
 
== Resources    ==


add appropriate resources here  
add text here relating to key evidence with regards to any of the above headings<br>


== Case Studies  ==
<br>  
 
add links to case studies here (case studies should be added on new pages using the [[Template:Case Study|case study template]])<br>  


== References  ==
== References  ==
References will automatically be added here, see [[Adding References|adding references tutorial]].


<references />
<references />

Revision as of 08:00, 3 July 2020

Introduction[edit | edit source]

Body complications.jpg

Enteropathic spondylitis, or EA, is a form of chronic, inflammatory arthritis associated with the occurrence of an inflammatory bowel disease (IBD), the two best-known types of which are ulcerative colitis and Crohn’s disease.

  • About one in five people with Crohn’s or ulcerative colitis will develop enteropathic arthritis.
  • The most common areas affected by EnA are the peripheral (limb) joints and, in some cases, the entire spine can become involved, as well[1].

Etiology/Epidemiology[edit | edit source]

The results from epidemiologic studies on AE affected byby several factors, including the lack of validated sets of diagnostic criteria, the frequency of IBD in different geographic areas, the age cut-off and case definition, and different study designs.

The incidence and prevalence of IBD

  • Western Countries is estimated to be 6-15/100,000
  • 50-200/100,000 for developed countries CD
  • 8-14/100,000 and 120-200/100,000 for underdeveloped countries UC.

Rheumatic manifestations are the most frequent extraintestinal manifestation in IBD patients with a prevalence ranging between 17% and 39%

  • The joint involvement observed in IBD is usually classified in two subsets: axial (including sacroiliitis with or without spondylitis) and peripheral.
  • The axial involvement is found to be present in 2%–16% of IBD patients, with a higher prevalence in CD patients than in UC ones.
  • The prevalence of sacroiliitis (asymptomatic and symptomatic) is between 12% and 20% and association with HLA-B27 ranged from 3.9% to 18.9%.
  • The peripheral involvement is a common complication in both CD and UC and its prevalence has been reported in a wide range (0.4%–34.6%) of patients with IBD. Predominantly affects the joints of the lower limbs.
  • Women show more frequently a peripheral joint involvement, whereas men tend to have an axial involvement.
  • Potential risk factors for arthritis in IBD patients are active bowel disease, family history of IBD, appendectomy, cigarette smoking, and the presence of others extraintestinal manifestations, such as erythema nodosum or pyoderma gangrenosum[2]

Mechanism of Injury / Pathological Process[edit | edit source]

  • The pathogenesis of EA is not fully understood - observationally joint inflammation occurs in genetically predisposed subjects with bacterial gut infections (providing important evidence for a possible relationship between inflammation of the gut mucosa and arthritis).
  • More than two-third of patients with SpA (spondyloarthritis) show microscopic inflammatory changes of gut mucosa without clinical signs of gastrointestinal disease.
  • Current theories prepose that genetically predisposed subjects have an aberrant migration of intestinal lymphocytes or macrophages from inflamed gut mucosa to joints.
  • A dysfunctional interaction between the mucosal immune system and gut bacteria could result in an abnormal state of immunological tolerance toward flora by alterations in mucosal effector cells or by affecting regulatory cells.[2]

Clinical Presentation[edit | edit source]

The symptoms of enteropathic arthritis (EnA) can be divided in two groups:

  1. Symptoms of inflammatory bowel disease (IBD) see Link
  2. Arthritic symptoms in the joints and, possibly, see below.[1]
  • About one in five people with EnA will have inflammatory arthritis in one or more peripheral (limb) joints eg an arm or leg, lower limbs are more commonly affected.
  • The severity of the peripheral arthritis normally coincides with the severity of the IBD, thus when diarrhea and abdominal pain are flaring, the peripheral arthritis tends to flare, as well.
  • About one in six people with IBD also has spinal inflammation, this is independent of the severity of the bowel disease symptoms.
  • In many people, this may just be arthritis in the sacroiliac (SI) joints, but in about five percent of people, the entire spine is involved.

Note that arthritis symptoms may precede the IBD symptoms[1].

Diagnostic Procedures[edit | edit source]

A diagnosis of enteropathic arthritis is made through a complete medical examination including a history of symptoms and taking into account family history. Various tests may also be done:

  • A stool culture may be taken if a diagnosis of an inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease has not yet been established.
  • A colonoscopy with or without bowel biopsies.
  • Blood tests may be done including an erythrocyte sedimentation rate (ESR or SED Rate), which may help in detecting inflammation, a test to determine the presence of the HLA-B27 genetic marker, and/or a C-reactive protein, which is another test that may help detect the presence of inflammation in the body.
  • Synovial fluid may be taken from affected joints for study.
  • X-rays of affected joints.[2]

Management / Interventions[edit | edit source]

A common treatment regimen for the various forms of spondyloarthritis (ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis, reactive arthritis, juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves

Medication -

  • In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted so the gastrointestinal component of the disease is also treated and not exacerbated.
  • The use of corticosteroids and/or DMARDs and/or of anti-TNFα, helpful to contain intestinal inflammation, usually leads also to the reduction of peripheral arthritis symptoms.
  • Intra-articular injections of steroids[2]

Physical therapy - including

  • Exercise (strength and range of movement)
  • Good posture practices
  • Mobilisations and massage
  • Other options eg heat/cold to help relax muscles and reduce joint pain[1].

Key Evidence[edit | edit source]

add text here relating to key evidence with regards to any of the above headings


References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 SAA Enteropathic spondylitis Available from:https://spondylitis.org/about-spondylitis/types-of-spondylitis/enteropathic-arthritis/ (last accessed 3.7.2020)
  2. 2.0 2.1 2.2 2.3 Peluso R, Di Minno MN, Iervolino S, Manguso F, Tramontano G, Ambrosino P, Esposito C, Scalera A, Castiglione F, Scarpa R. Enteropathic spondyloarthritis: from diagnosis to treatment. Clinical and Developmental Immunology. 2013 Jan 1;2013.Available from:https://www.hindawi.com/journals/jir/2013/631408/ (last accessed 3.7.2020)